ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana +10 more·2016·Nature Communications

DOI 10.1038/ncomms13837

Cited by (386)

Items 101–200 of 386

Prognostic role of ARID1A negative expression in gastric cancer
Mai Ashizawa, Motonobu Saito, Aung Kyi Thar Min, Daisuke Ujiie, Katsuharu Saito, Takahiro Sato, Tomohiro Kikuchi, Hirokazu Okayama, Shotaro Fujita, Hisahito Endo et al. · 2019 · Scientific Reports
An mRNA expression-based signature for oncogene-induced replication-stress
Sergi Guerrero Llobet, Arkajyoti Bhattacharya, Marieke Everts, Klaas Kok, Bert van der Vegt, Rudolf S.N. Fehrmann, Marcel A.T.M. van Vugt · 2022 · Oncogene
The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability
Jun Zhang, Feng Chen, Ming Tang, Wenchao Xu, Yuan Tian, Zhichao Liu, Yuxin Shu, Hui Yang, Qian Zhu, Xiaopeng Lu et al. · 2024 · Cell Reports
ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness
Qingyu Luo, Xiaowei Wu, Wan Chang, Pengfei Zhao, Yabing Nan, Xiaolin Zhu, Jonathan P. Katz, Dan Su, Zhihua Liu · 2019 · Cell Death and Differentiation
Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
Graeme Benstead-Hume, Xiangrong Chen, Suzanna R. Hopkins, Karen A. Lane, Jessica A. Downs, Frances M. G. Pearl · 2019 · PLoS Computational Biology
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications
Takeshi Fukumoto, Elizabeth Magno, Rugang Zhang · 2018 · Molecular Cancer Research
Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
Kazuaki Takahashi, Masataka Takenaka, Aikou Okamoto, David D.L. Bowtell, Takashi Kohno · 2021 · Cancers
Sophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer
Cedric R. Clapier · 2021 · International Journal of Molecular Sciences
Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma
Feng-Kun Zhang, Qian‐Zhi Ni, Kang Wang, Hui‐Jun Cao, Dongxian Guan, Er‐Bin Zhang, Ning Ma, Yikang Wang, Qian‐Wen Zheng, Sheng Xu et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase
Sarah Elizabeth Fordham, Helen J. Blair, Claire J. Elstob, Ruth Plummer, Yvette Drew, Nicola J. Curtin, Olaf T Heidenreich, Deepali Pal, David Jamieson, Catherine Park et al. · 2018 · Blood Advances
Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
Min Zhou, Jianlong Yuan, Yaqi Deng, Xianqun Fan, Jianfeng Shen · 2021 · Oncogenesis
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Yue Li, Xinhua Yang, Weijie Zhu, Yuxia Xu, Jiangjun Ma, Caiyun He, Fang Wang · 2022 · Cancer Cell International
A molecular classification of gastric cancer associated with distinct clinical outcomes and validated by an XGBoost-based prediction model
Bing Li, Fengbin Zhang, Qikai Niu, Jun Hong Liu, Yanan Yu, Pengqian Wang, Siqi Zhang, Huamin Zhang, Zhong Wang · 2022 · Molecular Therapy — Nucleic Acids
Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
Marco Volante, Özgür Mete, Giuseppe Pelosi, Anja Christiane Roden, Ernst‐Jan M. Speel, Silvia Uccella · 2021 · Endocrine Pathology
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers
Roman M. Chabanon, Daphné Morel, Sophie C. Postel-Vinay · 2019 · Seminars in Cancer Biology
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Natalie Y.L. Ngoi, Guang Peng, Timothy Anthony Yap · 2021 · Annual Review of Medicine
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer
Ying Ki Pang, Xu Chen, Tongjie Ji, Meng Cheng, Rui Wang, Chunyu Zhang, Min Liu, Jing Zhang, Chunlong Zhong · 2023 · Cancers
The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review
Bo Hu, Jianzhen Lin, Xiaobo Yang, Xinting Sang · 2020 · Cell Proliferation
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
Toshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, Misato Saito, Junya Tabata, Ryo Yokomizo, Daito Noguchi, Takafumi Kuroda, Ayako Kawabata, Jiro Suzuki et al. · 2021 · Scientific Reports
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Melinda L. Telli, Sara M. Tolaney, Geoffrey Ira Shapiro, Mark Ross Middleton, Simon Lord, Hendrik‐Tobias Arkenau, Andrew N.J. Tutt, Vandana Gupta Abramson, Emma Jane Dean, Tufia C. Haddad et al. · 2022 · npj Breast Cancer
ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications
Fukang Jin, Zhiguang Yang, Jingbo Shao, Jianxin Tao, Christoph Reißfelder, Sonja Loges, Lei Zhu, Sebastian Schölch · 2023 · Trends in Molecular Medicine
R-loops’ m6A modification and its roles in cancers
Yue Qiu, Changfeng Man, Luyu Zhu, Shiqi Zhang, Xiaoyan Wang, Dandan Gong, Yu Fan · 2024 · Molecular Cancer
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Leo Yamada, Motonobu Saito, Aung Kyi Thar Min, Katsuharu Saito, Mai Ashizawa, Koji Kase, Shotaro Nakajima, Hisashi Onozawa, Hirokazu Okayama, Hisahito Endo et al. · 2020 · Gastric Cancer
Epigenetic based synthetic lethal strategies in human cancers
Aiai Gao, Mingzhou Guo · 2020 · Biomarker Research
The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction
Vodicka, Pavel, Andera, Ladislav, Opattova, Alena, Vodickova, Ludmila · 2021 · Cancers
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
Mitsutake Yano, Tomomi Katoh, Mariko Miyazawa, Masaki Miyazawa, Naoki Ogane, Maiko Miwa, Kosei Hasegawa, Hisashi Narahara, Masanori Yasuda · 2019 · Scientific Reports
Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Deyin Xing, Gang Zheng, Aparna Pallavajjala, J. Kenneth Schoolmeester, Yuehua Liu, Lisa M. Haley, Yan Hu, Li Liu, Lisa Logan, Yuan Lin et al. · 2019 · Clinical Cancer Research
Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
Yun Gu, Puran Zhang, Jieti Wang, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang · 2022 · Cancer Immunology Immunotherapy
New therapies for clear cell ovarian carcinoma
James Stewart, Niamh Cunningham, Susana N. Banerjee · 2023 · International Journal of Gynecological Cancer
ARID1A mutations in cancer development: mechanism and therapy
Xuewei Zhang, Yixuan Zhang, Jinyi Zhao, Yinjie Wu, Na Zhang, Wenjing Shen · 2023 · Carcinogenesis
Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response
Benedikt Niedermaier, Ali Sak, Erika Zernickel, Shan Xu, Michael Groneberg, Martin Stuschke · 2019 · Scientific Reports
Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options
Helen J MacKay, Victor Rodriguez Freixinos, Gini F. Fleming · 2020 · American Society of Clinical Oncology Educational Book
Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
Li Wang, Jialin Qu, Na Zhou, Helei Hou, Man Jiang, Xiaochun Zhang · 2020 · Biomedicine & Pharmacotherapy
Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression
Changxiang Shi, Eun Ju Yang, Yifan Liu, Pui Kei Mou, Guowen Ren, Joong Sup Shim · 2020 · Oncogene
ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression
Qingyu Luo, Xiaowei Wu, Wan Chang, Pengfei Zhao, Xiaolin Zhu, Hongyan Chen, Yabing Nan, Aiping Luo, Xuantong Zhou, Dan Su et al. · 2020 · Cancer Research
Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities
Chang Xu, Kie Kyon Huang, Jia Hao Law, Joy Shijia Chua, Taotao Sheng, Natasha Mahealani Flores, Melissa Pool Pizzi, Atsushi Okabe, Angie Lay Keng Tan, Feng Zhu et al. · 2023 · Gut
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Shixuan Peng, Mengle Long, Qi-Sheng Chen, Zhijian Yin, Chang Zeng, Wanyong Zhang, Qingyang Wen, Xinwen Zhang, Weiqi Ke, Yongjun Wu · 2025 · Cell Death Discovery
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
Ah‐Rong Nam, Mei Hua Jin, Ji Eun Park, Ju‐Hee Bang, Do‐Youn Oh, Yung‐Jue Bang · 2018 · Cancer Research and Treatment
The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma
Motoyuki Tsuda, Akihisa Fukuda, Munenori Kawai, Osamu Araki, Hiroshi Seno · 2020 · Cancer Science
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
María Ovejero-Sánchez, Rogelio González‐Sarmiento, Ana Belén Herrero · 2023 · Cancers
Molecular Profile of Intrahepatic Cholangiocarcinoma
Wellington Andraus, Francisco Tustumi, José Donizeti de Meira Júnior, Rafael Soares Nunes Pinheiro, Daniel Reis Waisberg, Liliana Ducatti, Rubens Macedo Arantes, Vinicius Rocha‐Santos, Rodrigo Bronze de Martino, Luiz Augusto Carneiro D′Albuquerque · 2023 · International Journal of Molecular Sciences
The HNF-1β―USP28―Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma
Fuminori Ito, Chiharu Yoshimoto, Yuki Yamada, Tamotsu Sudo, Hiroshi Kobayashi · 2018 · Oncotarget
Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma
Javeed Iqbal, Catalina Amador, Timothy W. McKeithan, Wing Chung Chan · 2018 · Cancer treatment and research
Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing
Emma J. Chory, Jacob G. Kirkland, Chiung-Ying Chang, Vincent D. D’Andrea, Sai P. Gourisankar, Emily C. Dykhuizen, Gerald R. Crabtree · 2020 · ACS Chemical Biology
The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation
Xiang Li, Sen Tian, Hui Shi, Na Ta, Xiang Ni, Chenguang Bai, Zhanli Zhu, Yilin Chen, Dongchen Shi, Haidong Huang et al. · 2024 · Cancer Gene Therapy
Synthetic lethality: a step forward for personalized medicine in cancer
Heena Jariyal, Frank D. Weinberg, Abhinav Achreja, Deepak Nagarath, Akshay Srivastava · 2019 · Drug Discovery Today
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions
Hengzhou Zhu, Yuanyang Tian, Haoyan Chen, Yiyang Qian, Jiahui Li, Dong Niu, Wenyue Zhao, Yulin Wu, Xian Zhang, Tao Tang et al. · 2025 · Drug Resistance Updates
The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities
Júlia Varga, Marie Kube, Katja Luck, Sandra Schick · 2021 · Biochemical Society Transactions
ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
Xuan Cheng, Jianxiong Zhao, Feng Dong, Xuchen Cao · 2021 · Frontiers in Oncology
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
Ruth Plummer, Emma Jane Dean, Hendrik‐Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Young Chung, Jordi Ferrer-Playan, Thomas Goddemeier, Giuseppe Locatelli et al. · 2021 · Lung Cancer
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
Ukhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M. Miller Jenkins, Tapan Kumar Maity, Suresh Kumar, Frank T. Zenke, Naoko Takebe et al. · 2024 · Molecular Cancer Therapeutics
Epigenetics and immunotherapy in colorectal cancer: progress and promise
Tianjiao Dang, Xin Guan, Luying Cui, Yuli Ruan, Zhuo Chen, Haoyi Zou, Ya Lan, Chao Liu, Yanqiao Zhang · 2024 · Clinical Epigenetics
ARID1A Gene Driver Mutations in Lung Adenocarcinomas
Niki Karachaliou, Jillian Wilhelmina Paulina Bracht, Rafael Rosell · 2018 · Journal of Thoracic Oncology
Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
Patrick C. O’Leary, Huadong Chen, Yagmur Umay Doruk, Tess Williamson, Benjamin J. Polacco, Andrew S. McNeal, Tanushree Shenoy, Nupura Kale, Julia C. Carnevale, Erica J. Stevenson et al. · 2022 · Cancer Research
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets
Amalia A. Sofianidi, Ecaterina E Ileana Dumbrava, Konstantinos Nikolaos Syrigos, Azadeh Nasrazadani · 2024 · Cancers
XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
Reem Ali, Adel Alblihy, Michael S. Toss, Mashael Algethami, Rabab Al Sunni, Andrew R. Green, Emad A. Rakha, Srinivasan Madhusudan · 2020 · Therapeutic Advances in Medical Oncology
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
Reda Stankunaite, Sally L. George, Lewis Gallagher, Sabri Jamal, Ridwan Shaikh, Lina Yuan, Debbie Hughes, Paula Proszek, Paul M. Carter, Grzegorz Pietka et al. · 2021 · European Journal of Cancer
Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder
Stefan Garczyk, Nadina Ortiz‐Brüchle, Ursula Schneider, Isabella Lurje, Karolína Guricová, Nadine Therese Gaisa, Eva Lorsy, Katharina Lindemann-Docter, Axel Heidenreich, Ruth Knüchel · 2019 · American Journal Of Pathology
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
Natalie Y.L. Ngoi, Vignesh Sundararajan, David S.P. Tan · 2020 · International Journal of Gynecological Cancer
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Ioannis A. Voutsadakis · 2023 · Critical Reviews in Oncology/Hematology
Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency
Jie Wang, Haibo Yan, Qian Zhang, Wei‐Yan Liu, Ying-Hua Jiang, Gang Peng, Feizhen Wu, Xin Liu, Pengyuan Yang, Feng Liu · 2021 · Oncogene
The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer
Ieva Vaicekauskaitė, Rasa Sabaliauskaitė, Juozas Rimantas Lazutka, Sonata Jarmalaitė · 2022 · International Journal of Molecular Sciences
Mapping genetic interactions in cancer: a road to rational combination therapies
Beril Tutuncuoglu, Nevan J. Krogan · 2019 · Genome Medicine
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael F. Fay, Paul A. Tooney · 2021 · Cellular Oncology
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
Michele Bartoletti, Lucia Musacchio, Gaia Giannone, Valentina Tuninetti, Alice Bergamini, Giovanni Scambia, Domenica Lorusso, Giorgio Valabrega, Giorgia Mangili, Fabio Puglisi et al. · 2021 · Cancer Treatment Reviews
Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
Oscar Gee‐Wan Wong, Jing Li, Any Cheung · 2021 · Frontiers in Oncology
Temozolomide Sensitizes ARID1A -Mutated Cancers to PARP Inhibitors
Zheng-Cheng Yu, Tianhe Li, Ellen Tully, Peng Huang, Chih‐Ning Chen, Philipp Oberdoerffer, Stephanie L. Gaillard, Ie‐Ming Shih, Tian‐Li Wang · 2023 · Cancer Research
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing, Fandou Kong · 2024 · Journal of Ovarian Research
C17orf53 is identified as a novel gene involved in inter-strand crosslink repair
Chao Wang, Zhen Chen, Dan Su, Mengfan Tang, Litong Nie, Huimin Zhang, Xu Feng, Rui Wang, Xi Hua Shen, Mrinal Srivastava et al. · 2020 · DNA repair
Therapeutic significance of ARID1A mutation in bladder cancer
Marina Conde, Ian J. Frew · 2022 · Neoplasia
Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression
Norie Sugitani, Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva, Sandra Schamus-Haynes, Yiyang Wang, Drake Palmer, Hatice U. Osmanbeyoglu et al. · 2022 · Cell Reports
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays
Danyi Wang, Brian Elenbaas, Karthikeyan Murugesan, Kunal Shah, Meagan Montesion, Ioannis Gounaris, Juergen Scheuenpflug, Giuseppe Locatelli, Zheng Feng · 2023 · npj Precision Oncology
ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition
Lukas Kurz, Alissa Miklyaeva, Margaretha A. Skowron, Nina Overbeck, Gereon Poschmann, Teresa K. Becker, Katharina Eul, Thomas Kurz, Stefan Schönberger, Gabriele Calaminus et al. · 2020 · Cancers
Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset
Jin Hwa Hong, Hyun‐Woong Cho, Yung‐Taek Ouh, Jae Kwan Lee, Yikyeong Chun, Jeong‐An Gim · 2022 · Journal of Gynecologic Oncology
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations
Natalie Y.L. Ngoi, Shannon Neville Westin, Timothy Anthony Yap · 2022 · Current Opinion in Oncology
A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations
Ivana Stružinská, Nikola Hájková, Jan Hojny, Eva Krkavcová, Romana Michálková, Jiří Dvořák, Kristýna Němejcová, Radoslav Matěj, Ján Laco, Jana Drozenová et al. · 2023 · Diagnostic Pathology
Withaferin A inhibits expression of ataxia telangiectasia and Rad3‐related kinase and enhances sensitivity of human breast cancer cells to cisplatin
Eun‐Ryeong Hahm, Joomin Lee, Terric Abella, Shivendra Vikram Singh · 2019 · Molecular Carcinogenesis
Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase
Yunxin Duan, Haodong Cheng, Lili Zhuang, Jiawei Xia, Yerong Xu, Ruyue Zhang, Rui Sun, Tao Lu, Yadong Chen · 2023 · European Journal of Medicinal Chemistry
The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Michele Mascia, Marilia Barreca, Alberto J. Arribas, Luca Licenziato, Gaetanina Golino et al. · 2023 · British Journal of Haematology
Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication
Yu-Hsuan Hung, Ming-Chuan Hsu, Li-Tzong Chen, W. Hung, Mei-Ren Pan · 2019 · Journal of Clinical Medicine
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
Giovanni Centonze, Davide Biganzoli, Natalie Prinzi, Sara Pusceddu, Alessandro Mangogna, Elena Tamborini, Federica Perrone, Adele Busico, Vincenzo Lagano, Laura Cattaneo et al. · 2020 · Cancers
ARID1 Proteins: from Transcriptional and Post-Translational Regulation to Carcinogenesis and Potential Therapeutics
Olena Odnokoz, Cindy Wavelet-Vermuse, Shelby Lynn Hophan, Serdar Ekrem Bulun, Yong Wan · 2021 · Epigenomics
Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, Sammy, Barui, Sugata, McGee, Amberly M., Griffiths, Tamara, Singh, Pankaj K., Piett, Cortt G., Ghosh, Bidyut, Bhattacharyya, Sanchari, Singhi, Aatur, Pradhan, Kith et al. · 2020 · Cancers
Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Deepika Sirohi, Robert L. Schmidt, Dara L. Aisner, Amir Behdad, Bryan L. Betz, Noah A. Brown, Joshua F. Coleman, Christopher L. Corless, Georgios Deftereos, Mark David Ewalt et al. · 2019 · Journal of Molecular Diagnostics
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Fabian F. Pusch, Heathcliff Dorado García, Robin Xu, Dennis Gürgen, Yi Bei, Lotte Brückner, Claudia Röefzaad, Jennifer von Stebut, Victor Bardinet, Rocío Chamorro González et al. · 2023 · Molecular Cancer Therapeutics
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer
Naoki Kawahara, Kenji Ogawa, Mika Nagayasu, Mai Kimura, Yoshikazu Sasaki, Hiroshi Kobayashi · 2017 · Biomedical Reports
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response
Caitlin Murphy, Andrea M. Muscat, David M. Ashley, Violet Rudo Mukaro, Linda West, Yang Liao, David Chisanga, Wei Shi, Ian M Collins, Sally E. Baron-Hay et al. · 2019 · PLoS ONE
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
Saira Khalique, Sarah Nash, David Mansfield, Julian Wampfler, Ayoma D. Attygalle, Katherine M. Vroobel, Harriet Kemp, Richard Buus, Hannah Cottom, Ioannis Roxanis et al. · 2021 · Cancers
Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management
Daniel Schreyer, John P. Neoptolemos, Simon T. Barry, Peter Bailey · 2022 · Frontiers in Cell and Developmental Biology
BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage
Dan-Dan He, Xue-Ying Shang, Na Wang, Guang-Xing Wang, Kun-Yan He, Lan Wang, Ze-Guang Han · 2022 · Oncogene
Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer
Lan Wang, Chuan-Huai Deng, Qing Luo, Xianbin Su, Xueying Shang, Shu‐Jin Song, Sheng Cheng, Yu-Lan Qu, Xin Zou, Yi Y. Shi et al. · 2022 · Cancer Letters
Precision medicine for ovarian clear cell carcinoma based on gene alterations
Takafumi Kuroda, Takashi Kohno · 2020 · International Journal of Clinical Oncology
Current and future strategies for treatment of ovarian clear cell carcinoma
Aiko Ogasawara, Sho Sato, Kosei Hasegawa · 2020 · Journal of obstetrics and gynaecology research
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment
Sofia Genta, Federica Martorana, Anastasios Stathis, Ilaria Colombo · 2021 · Critical Reviews in Oncology/Hematology
Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy
Fabrice Viol, Bence Sipos, Martina Fahl, Till Sebastian Clauditz, Tania Amin, Malte Kriegs, Maike Nieser, Jakob Robert Izbicki, Samuel Huber, Ansgar Wilhelm Lohse et al. · 2022 · Cellular Oncology
Programmable DNA Hydrogel Assisting Microcrystal Formulations for Sustained Locoregional Drug Delivery in Surgical Residual Tumor Lesions and Lymph Node Metastasis
Zi‐jie Zhang, Yi Xin Zhou, Huan Tong, Xi‐cheng Sun, Zi‐cheng Lv, Junekong Yong, Yi‐chi Wu, Xue‐lin Xiang, Fei Ding, Xiaolei Zuo et al. · 2023 · Advanced Healthcare Materials
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study
Ignacio Romero, María Jesús Rubio, Manuel Hidalgo Medina, Xavier Matías‐Guiu, Marı́a Santacana, Juan-Antonio Schoenenberger, Eva Guerra, Alfonso Cortés, Lucas Minig, Pluvio Coronado et al. · 2020 · Gynecologic Oncology
Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
Luisa Maresca, Barbara A. Stecca, Laura Carrassa · 2022 · Cells
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
Shan Xu, Ali Sak, Benedikt Niedermaier, Yasin Bahadir Erol, Michael Groneberg, Emil Mladenov, MingWei Kang, George E. Iliakis, Martin Stuschke · 2022 · Frontiers in Oncology
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Timofey D. Lebedev, Rubina Kousar, Bbumba Patrick, Muhammad Usama, Meng-Kuei Lee, Ming Tan, Li X · 2023 · Cells